Lee, Byung-Wan
Cho, Young Min
Kim, Sin Gon
Ko, Seung-Hyun
Lim, Soo
Dahaoui, Amine
Jeong, Jin Sook
Lim, Hyo Jin
Yu, Jae Myung
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
https://doi.org/10.1007/s13300-023-01515-0
Article History
Received: 4 October 2023
Accepted: 20 November 2023
First Online: 18 January 2024
Declarations
:
: Byung-Wan Lee, Sin Gon Kim, Seung-Hyun Ko, Soo Lim, and Jae Myung Yu declare that there is no conflict of interest. Young Min Cho has received grants from Daewoong Pharmaceutical, Sanofi Korea and LG Chemical and has received consulting fees from LG Chemical. Amine Dahaoui, Jin Sook Jeong, and Hyo Jin Lim are employees of Novo Nordisk.
: The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice and was approved by an Institutional Review Board (Seoul National University Bundang Hospital [B-1705/395-002], The Catholic University of Korea, St. Vincent’s Hospital [VIRB-[sin]20170518-036], Seoul National University Hospital [H-1706-022-857], Severance Hospital [4-2017-0212], Korea University Anam Hospital [ED17090], Hallym University Kangnam Sacred Heart Hospital [HKS 2018-01-002]). Informed consent was obtained from all participants prior to enrolment in the study.